In our new series, ‘Inside Thryv - Conversations with Employees,’ we sit down with our team members to learn about their roles and how they help drive our mission forward. First up is Thryv’s President & Chief Development Officer, Debra Odink!

Lizzie hopes sharing her experiences raising a child with an ICD and diagnosed Long QT Type 15, she will reach people it can help.

The SADS Foundation is working with companies almost ready to recruit participants for first-of-their-kind clinical trials. But first, they need to learn more about the SADS community through this ten-minute survey so they can help connect you to research studies.

Three of our team were invited to join Dr. Michael Ackerman as part of the SADS Live program. We invite you to watch this interview to learn more about our passionate team and progress, what the next steps are as we move into clinical studies, and what we are doing to challenge the current LQTS treatments.

2022 was a big year for Thryv Therapeutics, and 2023 is shaping up to be even bigger. Debra Odink, President & Chief Development Officer, shares her wrap-up of the year.

Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers.

Two fireside chats by Mr. Paul F. Truex CEO on Thryv’s progress with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, atrial fibrillation and resistant cancers.

Results of SGK1 Inhibition in Patient- and Genotype Specific Re-Engineered Heart Cells with Congenital Long QT Syndrome and a model of Drug-Induced QT Prolongation to be presented at the AHA Scientific Sessions 2022 taking place November 5-7, 2022, in Chicago

We are pleased to appoint Dr. Debra Odink to President & CDO, and Dr. Shi Yin Foo to our Board. Both individuals bring impressive depth of development and company building expertise, which will be crucial as Thryv moves into clinical trials later this month.

We are excited to announce the evolution of our portfolio to include treatments for resistant and rare cancers. The new name, Thryv Therapeutics, embodies our commitment to relentlessly pursue therapies which provide lifelong benefits to patients, families, doctors, nurses and stakeholders.

Dr. Campeau will collaborate with Dr. McDonnell and his research team at Duke University to evaluate SGK1 inhibitors as potential treatments for people with breast and prostate cancer.

A major objective after our Series A financing, has been to enrich our Board with experienced, respected and highly accomplished drug development executives as we advance our clinical programs.

LQTT has completed US$19 million Series A financing led by Amplitude Ventures and included new investments from existing investors. We’re advancing a series of in-licensed compounds discovered and developed by Sanofi S.A. that inhibit SGK1.

In July 2021, a team of former Indiana University Swim Team are competing in the Trans Tahoe Relay race to raise awareness of Long QT Syndrome and the need for advanced treatments, while raising funds for 4-yr old Isla who has LQT3.

Amplitude Ventures exceeded their CAD$200M raise target and attracted investment from across the country and internationally. Amplitude is an early seed investor of LQTT.

Dr. Saumya Das, PhD MD, answers some tough questions about his research and the difficulties of treating individuals with a chronic syndrome.

Marc-Olivier Sirard, CPA, senior investment advisor at Fonds de solidarité FTQ, and Dr. Saumya Das, PhD, MD, Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Massachusetts General Hospital, join our board of directors.

Dave Hutton is a school teacher by profession, and a Long QT Syndrome caregiver by devotion. Upon his daughter Isla’s diagnosis with Long QT Syndrome Type 3 in 2016, Dave left teaching to be the full-time caregiver to his little girl.

Alexander Thomas is a 17 year-old dance prodigy born in South Florida. Alexander also has Long QT Syndrome, a condition shared by his mother, Palmire, and his brother, Adrien. This is their journey, shared with the LQTS community.

Research collaboration with the Mayo Clinic in Rochester, Minnesota to evaluate novel pharmacologic treatments for LQTS, an arrhythmia associated with a prolonged QT interval that can cause sudden death.